Authorship and contributorship
Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild to moderate asthma: a meta-analysis
Article first published online: 23 MAR 2012
© 2012 Blackwell Publishing Ltd
The Clinical Respiratory Journal
Volume 7, Issue 1, pages 74–90, January 2013
How to Cite
Yang, D., Luo, H., Wang, J., Bunjhoo, H., Xu, Y. and Xiong, W. (2013), Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild to moderate asthma: a meta-analysis. The Clinical Respiratory Journal, 7: 74–90. doi: 10.1111/j.1752-699X.2012.00287.x
Danlei Yang: performed study, collected data, Hao Luo: performed study, collected data, Jianmiao Wang: collected data, analysed data, Hansvin Bunjhoo: collected data, analysed data, Yongjian Xu: designed study, wrote the paper, Weining Xiong: designed study, wrote the paper.
Conflict of interest
The authors have stated explicitly that there are no conflicts of interest in connection with this article.
- Issue published online: 26 MAR 2013
- Article first published online: 23 MAR 2012
- Accepted manuscript online: 24 FEB 2012 06:41AM EST
- Received: 10 November 2011; Revision requested: 11 February 2012; Accepted: 20 February 2012
- bronchial asthma;
- inhaled corticosteroids;
- oral leucotriene receptor antagonist
Introduction: Inhaled corticosteroids (ICS) and oral leukotriene receptor antagonists (LTRA) are effective drugs used in the management of asthma as controller monotherapy in adolescents and adults, although there are debates as to which one is better.
Objectives: To thoroughly compare the efficacy and tolerability of ICS vs LTRA in adolescents and adults with mild to moderate asthma.
Methods: Relative database were searched for the review. Randomized controlled trials of more than or equal to 4 weeks' treatment duration comparing ICS with LTRA were reviewed.
Results and Conclusion: Twenty-four trials with 6197 randomized adolescents and adults with mild to moderate asthma met the inclusion criteria with a minimum duration of 4 weeks' treatment. Significant differences favouring ICS were found in all indices of pulmonary function. Other significant benefits of ICS were shown in symptoms, nocturnal awakenings, rescue-medication use, symptom-free days and quality of life. As to each special symptom of adverse effects, ICS was similar to LTRA in the incidence of headache, nausea and throat discomfort, but significantly higher in the incidence of hoarseness and oral pharyngeal candidiasis. Concerning withdrawal because of adverse events potentially related to treatment, ICS was similar to LTRA but significantly superior to LTRA in decreasing the asthma exacerbations or attacks during the treatment period. These results show that ICS may be the better drug in terms of efficacy and tolerability, except hoarseness and oral pharyngeal candidiasis, and should thus have priority over LTRA in asthma monotherapy in adolescents and adults.
Please cite this paper as: Yang D, Luo H, Wang J, Bunjhoo H, Xu Y and Xiong W. Comparison of inhaled corticosteroids and leukotriene receptor antagonists in adolescents and adults with mild to moderate asthma: a meta-analysis. Clin Respir J 2013; 7: 74–90.